相关实验视频

Updated: Sep 16, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

氨酸通过调节中性粒细胞外细胞陷来改善绝经后肥胖症

Anzhu Wang¹, Wei Zhang², Mengjiao Kang³

¹National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.

Scientific reports

|July 9, 2025

概括

绝经后的肥胖与炎症和中性粒细胞外细胞陷 (NETs) 有关. 在小鼠模型中,腺素治疗减少了肥胖标志物和NETs,这表明了潜在的治疗策略.

科学领域:

生殖生物学生殖生物学
免疫学免疫学免疫学
代谢障碍代谢障碍代谢障碍

背景情况:

绝经后与脂肪分布的改变和肥胖有关.
肥胖与慢性低度炎症有关.
中性粒细胞外细胞陷 (NETs) 在炎症和肥胖中发挥作用.

研究的目的:

研究差异表达基因 (DEGs) 在绝经后肥胖症中的作用.
探索腺在减轻肥胖症中的治疗潜力.
了解腺对NET和肥胖症炎症的影响.

主要方法:

从GEO数据库 (GSE44000) 中识别DEG.
蛋白与蛋白相互作用 (PPI) 网络构建和功能丰富分析.
使用卵巢切除 (OVX) 鼠标模型进行免疫透分析和体内研究.
评估基因表达和NETs标记物通过RT-qPCR和西方斑点.

主要成果:

确定了510个DEG,其中469个与炎症和免疫透相关的升调基因.
PPI分析揭示了参与NETs形成的关键基因.
在OVX小鼠中,腺素治疗减少了体重,脂肪和肝脂.
氨酸降低了NETs标志物 (ELANE,MPO) 和降低了TNF,ITGB2和ITGAM.

结论:

氨酸通过调节NETs标记物来改善绝经后的肥胖症.
炎症在肥胖病原发生过程中至关重要.
腺素为绝经后肥胖症提供了一种潜在的新疗法.

关键词:

亚丁氨酸 (Adenosine) 是一种氨基酸.炎症反应是一种炎症反应.中性粒细胞外细胞陷绝经后肥胖症绝经后肥胖症

更多相关视频

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

相关概念视频

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Adrenergic Receptors: β Subtype

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...